Trial Information

Summary: Linezolid Vs Vancomycin/Cefazolin in the Treatment of Hemodialysis Patients with Catheter-Related Gram-Positive Bloodstream Infections [A5951105]

The purpose of this research study is to find out if linezolid works in the treatment of catheter-related gram-positive infections in the bloodstream and that the treatment is safe. Linezolid (the study medication) will be compared to vancomycin/cefazolin (which are common treatments used for this infection). Linezolid, vancomycin and cefazolin are available by prescription and are approved for use by the FDA. However, none of these medications have been approved for the treatment of this type of infection.
Half of the patients will receive treatment with linezolid and half will receive treatment with vancomycin/cefazolin. Participation will last for a maximum of 84 days and patients may receive treatment with the study medication for up to 28 days.
All study procedures and medications will be provided at no cost.


No Compensation Provided

Patient Inclusion/Exclusion Criteria:

You may be eligible to participate if you
-are 18 years old or older
-are on hemodialysis
-have end stage renal disease
-have a catheter-related infection OR a fever OR a gram-positive blood culture
-meet additional criteria

You will not be able to participate if you
-are pregnant or breastfeeding
-have an infected catheter that cannot be removed
-have evidence of other infections

If you would like to learn more about participating in this study, please send an e-mail message using the form below.